With great fanfare, the Mayo Clinic won FDA approval late last year for a new diagnostic imaging agent that helps determine when prostate cancer has returned. But as Bloomberg reports, the non-profit medical center has struggled to expand access to the compound.
Researchers in the U.K. have found that an estrogen patch is an effective way to treat prostate cancer compared with side effects-laden hormone injections and pills.
A potential treatment for prostate cancer has an unlikely origin--a zoonotic disease. Scientists from Virginia Polytechnic Institute are tapping a Newcastle disease virus that kills prostate cancer cells, including hormone-resistant cells, but leaves normal cells intact, as a potential new drug.
MDxHealth ($MDXH) is celebrating positive results from recent studies of its prostate cancer molecular diagnostic test.
MDxHealth is celebrating positive results from recent studies of its prostate cancer molecular diagnostic test.
True Diagnostics gained a CE mark for its new quantitative prostate cancer diagnostic test, and the California startup will initially start selling it through distribution partners in Germany, the U.K., France, Italy and Spain.
Taiwanese drugmaker ScinoPharm will use Foresee Pharmaceuticals' controlled-release technology to produce a generic prostate cancer drug.
In a mouse study, stress stopped cancer drugs from working but beta blockers may kick-start the treatment again.
Researchers at Imperial College London have created a prototype ultra-sensitive visual test based on gold nanoparticles that can make detecting disease and infection biomarkers possible at a glance.
A protein that helps cells stick together could be a marker for the severity of prostate cancer, according to lab research at the U.K.'s University of Manchester. The protein, β2-syntrophin, helps cells make tight connections to each other, which helps to stop tumors from spreading.